why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat

Course:

CME Credits: 1.00

Released: 2025-04-29

In recent years, treatment options for bladder cancer have rapidly advanced. The 2024 NCCN Guidelines outline new first-line therapeutic options, integrating immune checkpoint inhibitors, antibody-drug conjugates, and multiple options for second and subsequent lines of therapy, including targeted agents. Clinicians must be aware of these practice-changing updates and how to incorporate them safely and effectively into treatment plans for appropriate patients. In two 30-minute online, on-demand sessions, join Drs. Neal Shore and Petros Grivas as they discuss first-line options for previously untreated urothelial carcinoma, practice implications, and best practices for the management of adverse events. The second session is intended to address challenges in community care practices related to the implementation of the new standard of care for first-line treatment of mUC and AE management.


View Full Course